陕西盘龙药业集团股份有限公司 2026年1月16日 关于完成第五届董事会董事补选的公告 特此公告。 陕西盘龙药业集团股份有限公司董事会 证券代码：002864 证券简称：盘龙药业 公告编号：2026-002 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于2026年1月16日召 开2026年第一次临时股东会，审议通过了《关于补选第五届董事会董事的议案》， 同意选举孟重先生为公司第五届董事会非独立董事。任期自股东会审议通过之日 起至本届董事会任期届满之日止。公司第五届董事会中兼任公司高级管理人员以 及由职工代表担任的董事人数总计不超过公司董事总数的二分之一。孟重先生简 历详见公司于2025年12月30日在巨潮资讯网(http://www.cninfo.com.cn)披露的 《关于调整公司董事及高级管理人员的公告》。 1 ...

北京瑞强律师事务所 二零二六年一月 0 地 址：北京市东城区银河 SOHO B 座 1509-1510 室 电 话：010-58116099 传 真：010-58116099 Email：Recher@bjrecher.com 关于陕西盘龙药业集团股份有限公司 2026 年第一次临时股东会 之 法律意见书 北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2026 年第一次临时股东会 之 法律意见书 北京瑞强律师事务所（以下简称"本所"）接受陕西盘龙药业集团股份有限公 司（以下简称"公司"）的委托，指派本所陈晓昀律师、王志恒律师出席公司于 2026 年 1 月 16 日下午 14:00 在陕西省西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开的 2026 年第一次临时股东会 （以下简称"本次股东会"）。现依据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交 易所上市公司股东会网络投票实施细则》（以下简称"《网络投票细则》"）《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、其他规 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2026-001 陕西盘龙药业集团股份有限公司 关于 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况： （一）会议召开时间： 1.现场会议召开日期：2026 年 1 月 16 日（星期五）下午 14:00。 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2026 年 1 月 16 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为 2026 年 1 月 16 日 9:15—15:00 期间的任意时间。 （二）现场会议召开地点：西安市灞桥区现代纺织产业园灞柳二路2801号陕 西盘龙医药股份有限公司二楼会议室。 （三）会议召开和表决方式：采用现场表决与网络投票相结合的方式。 （四）召集人：董事会。 （五）会议主持人：董事长谢晓林先生。 （六）本 ...

证券之星消息，1月16日中药板块较上一交易日下跌0.59%，*ST长药领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600671 | 天目药业 | 18.41 | 4.07% | 4.04万 | | 7418.12万 | | 002317 | 众生药业 | 22.10 | 3.32% | 86.21万 | | 18.54亿 | | 300878 | 维康药业 | 32.84 | 2.34% | 1 6.12万 | | 2.07亿 | | 002864 | 盘龙药业 | 36.60 | 1.86% | 8.27万 | | 2.97亿 | | 301331 | 恩威医药 | 28.96 | 1.79% | 1.86万 | | 5360.93万 | | 002107 | 沃华医药 | 7.49 | 1.49% | 23.71万 | | 1.78亿 | | ...

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

Group 1 - The company held its fifth board meeting on December 26, 2025, with all nine directors present, including one attending via telecommunication [2][3] - The board approved several resolutions, including the completion of fundraising projects and the permanent allocation of surplus funds to working capital, with unanimous support [3][4] - A short-term loan application of 50 million yuan from China Agricultural Bank was also approved, with two related directors abstaining from the vote [4][5] Group 2 - The board approved the adjustment of directors and senior management, which will require shareholder approval [7][8] - A proposal to convene the first extraordinary general meeting of shareholders in 2026 was also passed unanimously [10] - The meeting is scheduled for January 16, 2026, with provisions for both on-site and online voting [11][12]

Group 1 - The company, Panlong Pharmaceutical (002864), announced that it will hold its first extraordinary general meeting of shareholders for 2026 on January 16, 2026, at 14:00 [1]

Core Viewpoint - Panlong Pharmaceutical announced the approval of several proposals, including the conclusion of fundraising projects and the permanent allocation of surplus funds to supplement working capital [2] Group 1 - The third meeting of the fifth board of directors of Panlong Pharmaceutical was held [2] - The company approved the proposal regarding the conclusion of fundraising projects [2] - Surplus funds from the fundraising will be permanently allocated to enhance working capital [2]

Group 1 - The core point of the article is that Panlong Pharmaceutical announced the convening of its fifth board meeting to discuss adjustments to its board and senior management personnel [1] - The meeting will take place on December 26, 2025, in Xi'an, Shaanxi Province, combining both in-person and remote participation [1] - For the first half of 2025, Panlong Pharmaceutical's revenue composition shows that pharmaceutical manufacturing and sales accounted for 99.34%, while other segments contributed 0.52% and health products made up 0.14% [1] Group 2 - As of the report, Panlong Pharmaceutical has a market capitalization of 3.3 billion yuan [2]